ArticleThe Lancet. Infectious diseases2022
Global impact of the first year of COVID-19 vaccination: a mathematical modelling study.
Article in The Lancet. Infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 877 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
877 citing papers in PubMed, 6 syntheses or guidelines pooled it, 1,785 citations in OpenAlex.
- Identification of metabolic signatures of immune response following mRNA and inactivated vaccines against COVID-19: a systematic review.Frontiers in immunology · 2026Pooled it
- Myocarditis and Pericarditis are Temporally Associated with BNT162b2 COVID-19 Vaccine in Adolescents: A Systematic Review and Meta-analysis.Pediatric cardiology · 2025Pooled it
- Racial and ethnic disparities in COVID-19 vaccination: a systematic review and meta-analysis.Archives of public health = Archives belges de sante publique · 2025Pooled it
- The efficacy and effectiveness of COVID-19 vaccines in Iran: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Federated Learning-Based Model for Predicting Mortality: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2025Pooled it
- Association of gross domestic product with equitable access to childhood vaccines in 195 countries: a systematic review and meta-analysis.BMJ global health · 2025Pooled it
- Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18-55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Trial.The Journal of infectious diseases · 2026Trial
- Effectiveness of a video-based intervention for COVID-19 vaccine acceptance among individuals with mental disorders: a randomized online experiment.Frontiers in public health · 2026Trial
- Interventions to reduce vaccine hesitancy among adolescents: a cluster-randomized trial.Nature human behaviour · 2026Trial
- Colostrum from MERS-CoV seropositive camels for MERS prophylaxis and SARS-CoV-2 infection, a placebo controlled randomized trial.Scientific reports · 2025Trial
- Effects of a Theory- and Evidence-Based, Motivational Interviewing-Oriented Artificial Intelligence Digital Assistant on Vaccine Attitudes: A Randomized Controlled Trial.Journal of medical Internet research · 2025Trial
- Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomized Phase III trial.Antimicrobial agents and chemotherapy · 2025Trial
- Economic and health consequence frames affect COVID-19 vaccine incentive attitudes in Germany- a survey based framing experiment.BMC public health · 2025Trial
- Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans.Nature microbiology · 2025Trial
- Safety of COVID-19 mRNA-1273 booster doses in Asian populations: A literature review of post-marketing observational studies.Human vaccines & immunotherapeutics · 2026Review
- Waning immunity and the future of booster vaccination strategies in global vaccine programs post COVID-19.Human vaccines & immunotherapeutics · 2026Review
- COVID vaccination and economic game decisions: The role of analytical thinking.Human vaccines & immunotherapeutics · 2026Article
- Agreement between seroprevalence- and model-based estimates of COVID-19 burden.Global health action · 2026Article
- Postpandemic COVID-19 Vaccination Willingness Among Physicians and Medical Trainees in China: Cross-Sectional Study.JMIR public health and surveillance · 2026Article
- Assessing the impact of the COVID-19 pandemic on routine childhood vaccination uptake, the Netherlands, 2016 to 2025.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
817 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe first COVID-19 vaccine outside a clinical trial setting was administered on Dec 8, 2020. To ensure global vaccine equity, vaccine targets were set by the COVID-19 Vaccines Global Access (COVAX) Facility and WHO. However, due to vaccine shortfalls, these targets were not achieved by the end of 2021. We aimed to quantify the global impact of the first year of COVID-19 vaccination programmes.
methodsA mathematical model of COVID-19 transmission and vaccination was separately fit to reported COVID-19 mortality and all-cause excess mortality in 185 countries and territories. The impact of COVID-19 vaccination programmes was determined by estimating the additional lives lost if no vaccines had been distributed. We also estimated the additional deaths that would have been averted had the vaccination coverage targets of 20% set by COVAX and 40% set by WHO been achieved by the end of 2021.
findingsBased on official reported COVID-19 deaths, we estimated that vaccinations prevented 14·4 million (95% credible interval [Crl] 13·7-15·9) deaths from COVID-19 in 185 countries and territories between Dec 8, 2020, and Dec 8, 2021. This estimate rose to 19·8 million (95% Crl 19·1-20·4) deaths from COVID-19 averted when we used excess deaths as an estimate of the true extent of the pandemic, representing a global reduction of 63% in total deaths (19·8 million of 31·4 million) during the first year of COVID-19 vaccination. In COVAX Advance Market Commitment countries, we estimated that 41% of excess mortality (7·4 million [95% Crl 6·8-7·7] of 17·9 million deaths) was averted. In low-income countries, we estimated that an additional 45% (95% CrI 42-49) of deaths could have been averted had the 20% vaccination coverage target set by COVAX been met by each country, and that an additional 111% (105-118) of deaths could have been averted had the 40% target set by WHO been met by each country by the end of 2021.
interpretationCOVID-19 vaccination has substantially altered the course of the pandemic, saving tens of millions of lives globally. However, inadequate access to vaccines in low-income countries has limited the impact in these settings, reinforcing the need for global vaccine equity and coverage.
fundingSchmidt Science Fellowship in partnership with the Rhodes Trust; WHO; UK Medical Research Council; Gavi, the Vaccine Alliance; Bill & Melinda Gates Foundation; National Institute for Health Research; and Community Jameel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.